Novo Nordisk Needs to Invest in Its RNAi Tools

**Sometimes the biggest problems have the simplest solutions. For Novo Nordisk, reigniting the growth engine means unleashing the RNAi platform it acquired in December 2021.** Despite wielding a top 3 RNAi platform, the pharma leader has curiously handicapped its contributions. That strategic error is now evident as investors and analysts worry about future growth prospects. Making meaningful investments in internal RNAi tools and capabilities seems like an easy solution to many of the company's problems. Novo Nordisk could protect the obesity portfolio with next-gen assets, support other promising drug candidates such as the NLRP3 inhibitor (inflammation / immunology), and develop specific therapeutic areas with the sole intention of monetizing the R&D. This article walks through promising early results for next-gen obesity targets from Wave Life Sciences and Arrowhead, the opportunity to develop complement-mediated assets, and potentially more ambitious bets. For example, Dicerna Pharma had a phase 1 drug candidate called DCR-AUD for alcohol use disorder. It's one of the few commercial opportunities that could rival obesity with \~283 million individuals globally and over 10 million in the United States. [https://www.living.tech/articles/novo-nordisk-isnt-this-incompetent](https://www.living.tech/articles/novo-nordisk-isnt-this-incompetent)